<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350207</url>
  </required_header>
  <id_info>
    <org_study_id>205.342</org_study_id>
    <nct_id>NCT00350207</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg</brief_title>
  <official_title>A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose Inhaler (2 Actuations of 25 Mcg Twice Daily) in Moderate Persistent Asthma Patients With the B16-Arg/Arg Genotype</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      This is a 16 week multicentre, multinational, randomised, double-blind, double-dummy,
      placebo-controlled, parallel group study to evaluate the long-term efficacy and safety of
      tiotropium compared to salmeterol in moderate persistent asthmatic (GINA step 3) patients
      homozygous for arginine at the 16th amino acid position of the beta-adrenergic receptor
      (ADRB2). Following an initial 4-week run-in period on salmeterol MDI patients will be
      randomised into the 16 week double-blind treatment period in which they receive either
      tiotropium once daily administered from the Respimat inhaler or salmeterol twice daily
      administered from the hydrofluoro-alkane Metered Dose Inhaler (MDI), or placebo twice daily.
      After the 16 week treatment period all patients will receive salmeterol MDI twice daily for
      four weeks.

      The patients perform daily morning and evening peak flow (PEF) and Forced Expiratory Volume
      in the First Second (FEV1) measurements with an electronic peak flow meter throughout the
      study. Daily data on asthma control and use of rescue medication are recorded using an
      electronic diary included in the electronic peak flow meter. On study visits the Mini-Asthma
      Quality of Life Questionnaire (Elizabeth Juniper) is administered, pulse and blood pressure
      and pre-dose pulmonary function testing (FEV1 and Forced Vital Capacity) are performed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial</measure>
    <time_frame>baseline and after 16 weeks of treatment</time_frame>
    <description>Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Peak Expiratory Flow at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Mean weekly morning peak expiratory flow at week 4, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Peak Expiratory Flow at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Mean weekly morning peak expiratory flow at week 8, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Peak Expiratory Flow at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Mean weekly morning peak expiratory flow at week 12, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Peak Expiratory Flow at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Mean weekly morning peak expiratory flow at week 16, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Peak Expiratory Flow at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Mean weekly evening peak expiratory flow at week 4, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Peak Expiratory Flow at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Mean weekly evening peak expiratory flow at week 8, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Peak Expiratory Flow at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Mean weekly evening peak expiratory flow at week 12, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Peak Expiratory Flow at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Mean weekly evening peak expiratory flow at week 16, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms in the Morning&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-AQLQ Overall Score at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mini-AQLQ Overall Score at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure in Conjunction With Spirometry at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Systolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure in Conjunction With Spirometry at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Systolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure in Conjunction With Spirometry at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Systolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Diastolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Diastolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Diastolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate in Conjunction With Spirometry at Visit 3</measure>
    <time_frame>After 6 weeks of treatment</time_frame>
    <description>Pulse rate collected in conjunction with spirometry at 6 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate in Conjunction With Spirometry at Visit 4</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>Pulse rate collected in conjunction with spirometry at 12 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse Rate in Conjunction With Spirometry at Visit 5</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>Pulse rate collected in conjunction with spirometry at 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PEF Variability at Week 4</measure>
    <time_frame>After 4 weeks of treatment</time_frame>
    <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PEF Variability at Week 8</measure>
    <time_frame>After 8 weeks of treatment</time_frame>
    <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PEF Variability at Week 12</measure>
    <time_frame>After 12 weeks of treatment</time_frame>
    <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean PEF Variability at Week 16</measure>
    <time_frame>After 16 weeks of treatment</time_frame>
    <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
  </secondary_outcome>
  <enrollment type="Actual">388</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium bromide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salmeterol xinafoate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion_Criteria:

          1. Patients homozygous for arginine at the 16th amino acid position of the beta2
             adrenergic receptor (B16 Arg/Arg)

          2. All patients must sign and date an Informed Consent Form for the study prior to
             participation in the trial

          3. Male or female outpatients with at least 18 years of age, but not older than 65 years

          4. Patients must have a documented history of asthma

          5. Patients must be current non-smokers or ex-smokers with a cigarette smoking history of
             &lt;10 pack-years

          6. Patients must be on a maintenance treatment with inhaled corticosteroids with a total
             daily dose of 400 - 1000 mcg budesonide or equivalent

        Exclusion_Criteria:

          1. Patients with a significant disease other than asthma

          2. Patients with a recent history (i.e., six months or less) of myocardial infarction

          3. Patients who have been hospitalized for heart failure (New York Heart Association
             class III or IV) within the past year

          4. Patients with any unstable or life threatening cardiac arrhythmia or cardiac
             arrhythmia requiring intervention or a change in drug therapy within the past year

          5. Patients with malignancy for which the patient has undergone resection, radiation
             therapy or chemotherapy within the last five years. Patients with treated basal cell
             carcinoma are allowed.

          6. Patients with a diagnosis of chronic obstructive pulmonary disease (COPD)

          7. Patients with a history of life threatening pulmonary obstruction, or a history of
             cystic fibrosis or clinically evident bronchiectasis

          8. Patients with known active tuberculosis

          9. Patients who have undergone thoracotomy with pulmonary resection.

         10. Patients who have completed a pulmonary rehabilitation program in the six weeks prior
             to visit 1 or patients who are currently in a pulmonary rehabilitation program that
             will not be maintained throughout the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>205.342.43002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trofaiach</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.43007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Anderlecht</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Angleur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brussel</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32014 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Herentals</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Malmédy</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Menen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montigny-le-Tilleul</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Namur</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Turnhout</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.32013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.45003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.45001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.45002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kobenhavn NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.45004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Odense C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.35803 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.35801 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.35802 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lahti</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.35804 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3305A Centre Hosp de la Cavale Blanche</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3304A Cabinet Médical</name>
      <address>
        <city>Chamalières</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3307A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3301A UCP-X - Clinique Médicale</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3302A Hôpital Arnaud de Villeneuve</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3306A Mediscis</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3308A Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Pierre la Réunion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.3308B Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Saint Pierre la Réunion</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Beelitz-Heilstätten</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bruchsal</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Frankfurt/Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kassel</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Köln</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Minden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Neuruppin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rathenow</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rüdersdorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Weinheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kavala</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Larisa</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.30003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39003 Azienda Ospedaliera &quot; S. Anna&quot;</name>
      <address>
        <city>Ferrara</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39006 Azienda Ospedaliera Universitaria Careggi</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39005 Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39002 Università di Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Orbassano (to)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39007 Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39001 Ospedale di Cisanello</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.39009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sesto San Giovanni (mi)</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.07008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Trencin</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.42108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bellville</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bloemfontein</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centurion</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>George</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.27005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34006 Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34004 Hospital General Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34002 Hospital de Gran Canaria Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34007 Hospital Universitari Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34003 Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34009 Hospital Universio Puerta del Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34008 Hospital Universitario Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34005 Hospital Vírgen de la Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.34010 Hospital General Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90007 Istanbul Universitesi Cerrahpasa Tip Fakultesi</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90005 Kocaeli Universitesi Tip Fakultesi</name>
      <address>
        <city>Izmit</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.90004 Celal Bayar Universitesi Tip Fakultesi</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.44002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Aylesbury</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chertsey</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.44003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greenisland</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.44006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205.342.44005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2006</study_first_submitted>
  <study_first_submitted_qc>July 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2006</study_first_posted>
  <results_first_submitted>August 24, 2009</results_first_submitted>
  <results_first_submitted_qc>October 8, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 17, 2009</results_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 24, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Bromides</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium</title>
          <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
        </group>
        <group group_id="P2">
          <title>Salmeterol</title>
          <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="128"/>
                <participants group_id="P2" count="134"/>
                <participants group_id="P3" count="126"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="119"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Treated set includes all patients who were dispensed randomised study medication and were documented to have taken at least one dose of investigational treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Tiotropium</title>
          <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
        </group>
        <group group_id="B2">
          <title>Salmeterol</title>
          <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="128"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="126"/>
            <count group_id="B4" value="388"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.5" spread="12.6"/>
                    <measurement group_id="B2" value="42.3" spread="13.4"/>
                    <measurement group_id="B3" value="44.0" spread="11.9"/>
                    <measurement group_id="B4" value="43.3" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial</title>
        <description>Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit</description>
        <time_frame>baseline and after 16 weeks of treatment</time_frame>
        <population>The Full analysis set (FAS) included patients who received at least one dose of randomised study medication and who had at least four patient diary records for at least one efficacy endpoint in any week after the first administration of the randomised treatment and baseline data for the corresponding efficacy endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Weekly Morning Peak Expiratory Flow From Baseline to the End of the Trial</title>
          <description>Change from baseline in mean weekly morning peak expiratory flow at 16 weeks. Baseline is defined as the last week prior to the randomisation visit</description>
          <population>The Full analysis set (FAS) included patients who received at least one dose of randomised study medication and who had at least four patient diary records for at least one efficacy endpoint in any week after the first administration of the randomised treatment and baseline data for the corresponding efficacy endpoint.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.93" spread="4.873"/>
                    <measurement group_id="O2" value="-3.15" spread="4.64"/>
                    <measurement group_id="O3" value="-24.63" spread="4.835"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Peak Expiratory Flow at Week 4</title>
        <description>Mean weekly morning peak expiratory flow at week 4, pre-dose</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Peak Expiratory Flow at Week 4</title>
          <description>Mean weekly morning peak expiratory flow at week 4, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.695" spread="4.244"/>
                    <measurement group_id="O2" value="359.762" spread="4.041"/>
                    <measurement group_id="O3" value="335.515" spread="4.211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Peak Expiratory Flow at Week 8</title>
        <description>Mean weekly morning peak expiratory flow at week 8, pre-dose</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Peak Expiratory Flow at Week 8</title>
          <description>Mean weekly morning peak expiratory flow at week 8, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.42" spread="4.646"/>
                    <measurement group_id="O2" value="350.53" spread="4.424"/>
                    <measurement group_id="O3" value="330.193" spread="4.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Peak Expiratory Flow at Week 12</title>
        <description>Mean weekly morning peak expiratory flow at week 12, pre-dose</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Peak Expiratory Flow at Week 12</title>
          <description>Mean weekly morning peak expiratory flow at week 12, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359.05" spread="4.885"/>
                    <measurement group_id="O2" value="351.3" spread="4.652"/>
                    <measurement group_id="O3" value="332.808" spread="4.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Peak Expiratory Flow at Week 16</title>
        <description>Mean weekly morning peak expiratory flow at week 16, pre-dose</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Peak Expiratory Flow at Week 16</title>
          <description>Mean weekly morning peak expiratory flow at week 16, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="355.619" spread="4.868"/>
                    <measurement group_id="O2" value="355.799" spread="4.636"/>
                    <measurement group_id="O3" value="334.525" spread="4.831"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Peak Expiratory Flow at Week 4</title>
        <description>Mean weekly evening peak expiratory flow at week 4, pre-dose</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Peak Expiratory Flow at Week 4</title>
          <description>Mean weekly evening peak expiratory flow at week 4, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="374.496" spread="4.249"/>
                    <measurement group_id="O2" value="366.219" spread="4.045"/>
                    <measurement group_id="O3" value="348.344" spread="4.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Peak Expiratory Flow at Week 8</title>
        <description>Mean weekly evening peak expiratory flow at week 8, pre-dose</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Peak Expiratory Flow at Week 8</title>
          <description>Mean weekly evening peak expiratory flow at week 8, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368.758" spread="4.78"/>
                    <measurement group_id="O2" value="359.586" spread="4.551"/>
                    <measurement group_id="O3" value="345.299" spread="4.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Peak Expiratory Flow at Week 12</title>
        <description>Mean weekly evening peak expiratory flow at week 12, pre-dose</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Peak Expiratory Flow at Week 12</title>
          <description>Mean weekly evening peak expiratory flow at week 12, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="366.282" spread="4.851"/>
                    <measurement group_id="O2" value="362.01" spread="4.617"/>
                    <measurement group_id="O3" value="344.291" spread="4.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Peak Expiratory Flow at Week 16</title>
        <description>Mean weekly evening peak expiratory flow at week 16, pre-dose</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Peak Expiratory Flow at Week 16</title>
          <description>Mean weekly evening peak expiratory flow at week 16, pre-dose</description>
          <population>FAS</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363.657" spread="5.242"/>
                    <measurement group_id="O2" value="360.304" spread="4.99"/>
                    <measurement group_id="O3" value="340.099" spread="5.198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4</title>
        <description>Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 4</title>
          <description>Mean weekly morning forced expiratory volume in 1 second at week 4, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.301" spread="0.026"/>
                    <measurement group_id="O2" value="2.316" spread="0.024"/>
                    <measurement group_id="O3" value="2.161" spread="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8</title>
        <description>Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 8</title>
          <description>Mean weekly morning forced expiratory volume in 1 second at week 8, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.254" spread="0.028"/>
                    <measurement group_id="O2" value="2.287" spread="0.027"/>
                    <measurement group_id="O3" value="2.164" spread="0.028"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12</title>
        <description>Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 12</title>
          <description>Mean weekly morning forced expiratory volume in 1 second at week 12, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.256" spread="0.03"/>
                    <measurement group_id="O2" value="2.254" spread="0.029"/>
                    <measurement group_id="O3" value="2.156" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16</title>
        <description>Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Morning Forced Expiratory Volume in 1 Second at Week 16</title>
          <description>Mean weekly morning forced expiratory volume in 1 second at week 16, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="0.03"/>
                    <measurement group_id="O2" value="2.278" spread="0.028"/>
                    <measurement group_id="O3" value="2.188" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4</title>
        <description>Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 4</title>
          <description>Mean weekly evening forced expiratory volume in 1 second at week 4, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.369" spread="0.029"/>
                    <measurement group_id="O2" value="2.318" spread="0.028"/>
                    <measurement group_id="O3" value="2.25" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8</title>
        <description>Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 8</title>
          <description>Mean weekly evening forced expiratory volume in 1 second at week 8, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.32" spread="0.03"/>
                    <measurement group_id="O2" value="2.301" spread="0.029"/>
                    <measurement group_id="O3" value="2.239" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12</title>
        <description>Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 12</title>
          <description>Mean weekly evening forced expiratory volume in 1 second at week 12, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.31" spread="0.032"/>
                    <measurement group_id="O2" value="2.299" spread="0.03"/>
                    <measurement group_id="O3" value="2.231" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16</title>
        <description>Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Evening Forced Expiratory Volume in 1 Second at Week 16</title>
          <description>Mean weekly evening forced expiratory volume in 1 second at week 16, pre-dose</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.343" spread="0.031"/>
                    <measurement group_id="O2" value="2.291" spread="0.029"/>
                    <measurement group_id="O3" value="2.215" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.267" spread="0.029"/>
                    <measurement group_id="O2" value="1.22" spread="0.027"/>
                    <measurement group_id="O3" value="1.232" spread="0.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.182" spread="0.027"/>
                    <measurement group_id="O2" value="1.176" spread="0.025"/>
                    <measurement group_id="O3" value="1.21" spread="0.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.203" spread="0.031"/>
                    <measurement group_id="O2" value="1.194" spread="0.03"/>
                    <measurement group_id="O3" value="1.224" spread="0.032"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Wake up During the Night Due to Asthma&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: Did not wake up, 2: Woke up once, 3: Woke up 2-5 times, 4: Woke up more than 5 times, 5: Was awake all night. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.196" spread="0.034"/>
                    <measurement group_id="O2" value="1.135" spread="0.033"/>
                    <measurement group_id="O3" value="1.185" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms in the Morning&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms in the Morning&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.612" spread="0.041"/>
                    <measurement group_id="O2" value="1.486" spread="0.038"/>
                    <measurement group_id="O3" value="1.615" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.504" spread="0.043"/>
                    <measurement group_id="O2" value="1.481" spread="0.041"/>
                    <measurement group_id="O3" value="1.613" spread="0.043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.519" spread="0.046"/>
                    <measurement group_id="O2" value="1.436" spread="0.045"/>
                    <measurement group_id="O3" value="1.542" spread="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms This Morning&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.536" spread="0.052"/>
                    <measurement group_id="O2" value="1.461" spread="0.051"/>
                    <measurement group_id="O3" value="1.647" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.735" spread="0.045"/>
                    <measurement group_id="O2" value="1.637" spread="0.043"/>
                    <measurement group_id="O3" value="1.744" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.603" spread="0.046"/>
                    <measurement group_id="O2" value="1.569" spread="0.043"/>
                    <measurement group_id="O3" value="1.699" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.572" spread="0.05"/>
                    <measurement group_id="O2" value="1.495" spread="0.049"/>
                    <measurement group_id="O3" value="1.682" spread="0.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Were Your Asthma Symptoms During the Day&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: No asthma symptoms, 2: Mild asthma symptoms, 3: Moderate asthma symptoms, 4: Severe asthma symptoms, 5: Very severe asthma symptoms. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.609" spread="0.054"/>
                    <measurement group_id="O2" value="1.476" spread="0.053"/>
                    <measurement group_id="O3" value="1.711" spread="0.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.549" spread="0.041"/>
                    <measurement group_id="O2" value="1.514" spread="0.039"/>
                    <measurement group_id="O3" value="1.583" spread="0.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.475" spread="0.041"/>
                    <measurement group_id="O2" value="1.478" spread="0.039"/>
                    <measurement group_id="O3" value="1.545" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.458" spread="0.045"/>
                    <measurement group_id="O2" value="1.436" spread="0.044"/>
                    <measurement group_id="O3" value="1.52" spread="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Limited Were You in Your Activities Today Because of Your Asthma&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: Not limited at all, 2: A little limited, 3: Moderately limited, 4: Severely limited, 5: Totally limited. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.446" spread="0.049"/>
                    <measurement group_id="O2" value="1.415" spread="0.047"/>
                    <measurement group_id="O3" value="1.593" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.699" spread="0.045"/>
                    <measurement group_id="O2" value="1.627" spread="0.043"/>
                    <measurement group_id="O3" value="1.735" spread="0.045"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.557" spread="0.047"/>
                    <measurement group_id="O2" value="1.571" spread="0.045"/>
                    <measurement group_id="O3" value="1.643" spread="0.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.048"/>
                    <measurement group_id="O2" value="1.482" spread="0.047"/>
                    <measurement group_id="O3" value="1.62" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;How Much Shortness of Breath Did You Experience During the Day&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: None, 2: A very little, 3: A moderate amount, 4: Quite a lot, 5: A very great deal. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.623" spread="0.057"/>
                    <measurement group_id="O2" value="1.482" spread="0.055"/>
                    <measurement group_id="O3" value="1.691" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 4</title>
        <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 4</title>
          <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.679" spread="0.048"/>
                    <measurement group_id="O2" value="1.605" spread="0.046"/>
                    <measurement group_id="O3" value="1.652" spread="0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 8</title>
        <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 8</title>
          <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.519" spread="0.05"/>
                    <measurement group_id="O2" value="1.56" spread="0.047"/>
                    <measurement group_id="O3" value="1.575" spread="0.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 12</title>
        <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 12</title>
          <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.539" spread="0.051"/>
                    <measurement group_id="O2" value="1.505" spread="0.05"/>
                    <measurement group_id="O3" value="1.572" spread="0.052"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 16</title>
        <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Weekly Score for Asthma Control Diary Question &quot;Did You Experience Wheeze or Cough During the Day&quot; at Week 16</title>
          <description>Unit on a scale 1-5. 1: Not at all, 2: A little of the time, 3: A moderate amount of the time, 4: Most of the time, 5: All the time. 1 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.528" spread="0.057"/>
                    <measurement group_id="O2" value="1.515" spread="0.056"/>
                    <measurement group_id="O3" value="1.669" spread="0.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3</title>
        <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 3</title>
          <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 6 weeks of treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.471" spread="0.031"/>
                    <measurement group_id="O2" value="2.401" spread="0.03"/>
                    <measurement group_id="O3" value="2.299" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4</title>
        <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 4</title>
          <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 12 weeks of treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.467" spread="0.031"/>
                    <measurement group_id="O2" value="2.442" spread="0.03"/>
                    <measurement group_id="O3" value="2.266" spread="0.031"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5</title>
        <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Expiratory Volume in 1 Second as Measured by Spirometry at Visit 5</title>
          <description>Morning pre-dose forced expiratory volume in 1 second as measured by spirometry after 16 weeks od treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.439" spread="0.03"/>
                    <measurement group_id="O2" value="2.457" spread="0.029"/>
                    <measurement group_id="O3" value="2.29" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3</title>
        <description>Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 3</title>
          <description>Morning pre-dose forced vital capacity as measured by spirometry after 6 weeks of treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.531" spread="0.034"/>
                    <measurement group_id="O2" value="3.441" spread="0.033"/>
                    <measurement group_id="O3" value="3.367" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4</title>
        <description>Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 4</title>
          <description>Morning pre-dose forced vital capacity as measured by spirometry after 12 weeks of treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.509" spread="0.035"/>
                    <measurement group_id="O2" value="3.495" spread="0.033"/>
                    <measurement group_id="O3" value="3.307" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5</title>
        <description>Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Morning Pre-dose Forced Vital Capacity as Measured by Spirometry at Visit 5</title>
          <description>Morning pre-dose forced vital capacity as measured by spirometry after 16 weeks of treatment</description>
          <population>FAS</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.488" spread="0.034"/>
                    <measurement group_id="O2" value="3.474" spread="0.033"/>
                    <measurement group_id="O3" value="3.353" spread="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3</title>
        <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ) Overall Score at Visit 3</title>
          <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.050" spread="0.067"/>
                    <measurement group_id="O2" value="5.259" spread="0.064"/>
                    <measurement group_id="O3" value="5.097" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-AQLQ Overall Score at Visit 4</title>
        <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-AQLQ Overall Score at Visit 4</title>
          <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.233" spread="0.066"/>
                    <measurement group_id="O2" value="5.399" spread="0.063"/>
                    <measurement group_id="O3" value="5.078" spread="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mini-AQLQ Overall Score at Visit 5</title>
        <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mini-AQLQ Overall Score at Visit 5</title>
          <description>Mean of the responses to 15 questions from 4 domains: Symptoms (1), Activity Limitations (2), Emotional Function (3), Environmental Stimuli (4). Unit on a scale 1-7. For domain (2): 1: totally limited, 2: extremely limited, 3: very limited, 4: moderate limitation, 5: some limitation, 6: a little limitation, 7: not at all limited. For other domains: 1: all of the time, 2: most of the time, 3: a good bit of the time, 4: some of the time, 5: a little of the time, 6: hardly any of the time, 7: none of the time. 7 is the best value</description>
          <population>FAS</population>
          <units>Unit on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.305" spread="0.068"/>
                    <measurement group_id="O2" value="5.454" spread="0.064"/>
                    <measurement group_id="O3" value="5.214" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 3</title>
        <description>Systolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 3</title>
          <description>Systolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.68" spread="14.53"/>
                    <measurement group_id="O2" value="123.11" spread="11.5"/>
                    <measurement group_id="O3" value="126.41" spread="14.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 4</title>
        <description>Systolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 4</title>
          <description>Systolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.81" spread="13.86"/>
                    <measurement group_id="O2" value="123.92" spread="12.15"/>
                    <measurement group_id="O3" value="125.18" spread="13.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 5</title>
        <description>Systolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure in Conjunction With Spirometry at Visit 5</title>
          <description>Systolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.23" spread="14.59"/>
                    <measurement group_id="O2" value="123.83" spread="12.82"/>
                    <measurement group_id="O3" value="124.47" spread="13.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3</title>
        <description>Diastolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 3</title>
          <description>Diastolic blood pressure collected in conjunction with spirometry at 6 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="126"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.62" spread="9.26"/>
                    <measurement group_id="O2" value="77.62" spread="8.74"/>
                    <measurement group_id="O3" value="79.34" spread="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4</title>
        <description>Diastolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 4</title>
          <description>Diastolic blood pressure collected in conjunction with spirometry at 12 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.88" spread="9.93"/>
                    <measurement group_id="O2" value="77.22" spread="9.23"/>
                    <measurement group_id="O3" value="78.29" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5</title>
        <description>Diastolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure in Conjunction With Spirometry at Visit 5</title>
          <description>Diastolic blood pressure collected in conjunction with spirometry at 16 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="122"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.23" spread="9.35"/>
                    <measurement group_id="O2" value="77.61" spread="7.92"/>
                    <measurement group_id="O3" value="78.38" spread="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate in Conjunction With Spirometry at Visit 3</title>
        <description>Pulse rate collected in conjunction with spirometry at 6 weeks</description>
        <time_frame>After 6 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate in Conjunction With Spirometry at Visit 3</title>
          <description>Pulse rate collected in conjunction with spirometry at 6 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="131"/>
                <count group_id="O3" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7" spread="8.8"/>
                    <measurement group_id="O2" value="74.9" spread="8.4"/>
                    <measurement group_id="O3" value="74.2" spread="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate in Conjunction With Spirometry at Visit 4</title>
        <description>Pulse rate collected in conjunction with spirometry at 12 weeks</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate in Conjunction With Spirometry at Visit 4</title>
          <description>Pulse rate collected in conjunction with spirometry at 12 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="129"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.8" spread="9.9"/>
                    <measurement group_id="O2" value="74.6" spread="9.2"/>
                    <measurement group_id="O3" value="74.2" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pulse Rate in Conjunction With Spirometry at Visit 5</title>
        <description>Pulse rate collected in conjunction with spirometry at 16 weeks</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pulse Rate in Conjunction With Spirometry at Visit 5</title>
          <description>Pulse rate collected in conjunction with spirometry at 16 weeks</description>
          <population>Treated set. Some patients discontinued the trial between Visits. Thus these patients are in the efficacy analysis for the respective period (are added in the participant flow) but they have no safety blood pressure/pulse rate measurements, because blood pressure and pulse rate were measured at Visits</population>
          <units>bpm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="128"/>
                <count group_id="O3" value="119"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" spread="9.9"/>
                    <measurement group_id="O2" value="75.3" spread="8.3"/>
                    <measurement group_id="O3" value="74.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PEF Variability at Week 4</title>
        <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
        <time_frame>After 4 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PEF Variability at Week 4</title>
          <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
          <population>FAS</population>
          <units>ratio expressed in percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.043" spread="0.611"/>
                    <measurement group_id="O2" value="10.547" spread="0.584"/>
                    <measurement group_id="O3" value="12.085" spread="0.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PEF Variability at Week 8</title>
        <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
        <time_frame>After 8 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PEF Variability at Week 8</title>
          <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
          <population>FAS</population>
          <units>ratio expressed in percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.377" spread="0.695"/>
                    <measurement group_id="O2" value="11.252" spread="0.664"/>
                    <measurement group_id="O3" value="12.964" spread="0.689"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PEF Variability at Week 12</title>
        <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
        <time_frame>After 12 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PEF Variability at Week 12</title>
          <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
          <population>FAS</population>
          <units>ratio expressed in percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.735" spread="0.654"/>
                    <measurement group_id="O2" value="11.320" spread="0.625"/>
                    <measurement group_id="O3" value="11.257" spread="0.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean PEF Variability at Week 16</title>
        <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
        <time_frame>After 16 weeks of treatment</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Tiotropium</title>
            <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
          </group>
          <group group_id="O2">
            <title>Salmeterol</title>
            <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Matching Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean PEF Variability at Week 16</title>
          <description>PEF (Peak expiratory flow) variability is defined as the difference between the highest morning PEF value and the highest evening PEF value of one day divided by the arithmetic mean of these two PEF values and multiplied by 100%</description>
          <population>FAS</population>
          <units>ratio expressed in percent</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="128"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.742" spread="0.656"/>
                    <measurement group_id="O2" value="10.793" spread="0.627"/>
                    <measurement group_id="O3" value="12.305" spread="0.650"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first study drug administration until 30 days after last randomised study drug administration</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tiotropium</title>
          <description>Tiotropium inhalation solution, 5mcg once daily PM</description>
        </group>
        <group group_id="E2">
          <title>Salmeterol</title>
          <description>Salmeterol Metered Aerosol, 50mcg twice daily</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Matching Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
              <event>
                <sub_title>Ligament injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 11.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="128"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="134"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="126"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Pharmaceuticals</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

